The FDA has cleared for marketing three computer-assisted detection technologies developed by iCAD: iDM, which works with Fischer Imaging's SenoScan full-field digital mammography system; iAD, a full-featured stand-alone unit, and iQ, a low-cost
The FDA has cleared for marketing three computer-assisted detection technologies developed by iCAD: iDM, which works with Fischer Imaging's SenoScan full-field digital mammography system; iAD, a full-featured stand-alone unit, and iQ, a low-cost stand-alone unit. Following the FDA approvals, iCAD and Fischer announced an expanded development and distribution agreement that includes the new iAD product, which reads digitized mammography films. iCAD, located in Nashua, NH, plans to market the device to women's health centers and breast clinics that perform fewer than 20 mammography procedures a day.
Mammography and Breast MRI: Is it Time to Evaluate Strategies as Opposed to Modalities?
July 5th 2024The combination of mammography with breast MRI within 90 days had a 96.2 percent sensitivity in comparison to 48.1 percent for mammography and 79.7 percent for breast MRI performed within 91 to 270 days after index mammography, according to newly published research.
ACR Collaborative Model Leads to 35 Percent Improvement with Mammography Positioning Criteria
July 1st 2024Noting significant variation with facilities for achieving passing criteria for mammography positioning, researchers found that structured interventions, ranging from weekly auditing of images taken by technologists to mechanisms for feedback from radiologists to technologists, led to significant improvements in a multicenter study.